The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Vericiguat (MK-1242) in Participants With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-035) (VICTOR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05093933
Recruitment Status : Active, not recruiting
First Posted : October 26, 2021
Last Update Posted : February 14, 2024
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of vericiguat in participants with chronic heart failure with reduced ejection fraction (HFrEF), specifically those with symptomatic chronic HFrEF who have not had a recent hospitalization for heart failure or need for outpatient intravenous (IV) diuretics. The primary hypothesis is that vericiguat is superior to placebo in reducing the risk of cardiovascular death or heart failure hospitalization.

Condition or disease Intervention/treatment Phase
Chronic Heart Failure With Reduced Ejection Fraction Drug: Vericiguat Drug: Placebo Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 6000 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction
Actual Study Start Date : November 2, 2021
Estimated Primary Completion Date : March 31, 2025
Estimated Study Completion Date : June 15, 2025

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure
Drug Information available for: Vericiguat

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Vericiguat
Participants receive a starting dose of 2.5 mg of vericiguat taken orally once daily. The vericiguat dose will be titrated to 5 mg and to 10 mg.
 Drug: Vericiguat
2.5, 5.0, or 10.0 mg orally once daily
Other Names:
  • MK-1242
  • BAY 1021189
Placebo Comparator: Placebo
Participants receive a starting matching placebo to vericiguat dose of 2.5 mg taken orally once daily. The matching placebo dose will be sham titrated to 5 mg and to 10 mg.
 Drug: Placebo
0 mg matching placebo for 2.5 mg, 5 mg, and 10 mg of vericiguat


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) Hospitalization [ Time Frame: From date of randomization until the date of first occurrence of a CV death or HF hospitalization, assessed up to approximately 40 months ]
    The first event of CV death or HF hospitalization as confirmed by a clinical events committee (CEC).


Secondary Outcome Measures :
  1. Time to First Occurrence of CV Death [ Time Frame: From date of randomization until the date of first occurrence of a CV death, assessed up to approximately 40 months ]
    The first event of CV death as confirmed by a CEC.

  2. Time to First Occurrence of HF Hospitalization [ Time Frame: From date of randomization until the date of first occurrence of a HF hospitalization, assessed up to approximately 40 months ]
    The first event of HF hospitalization as confirmed by a CEC.

  3. Time to Total HF Hospitalizations (Including First and Recurrent Events) [ Time Frame: Up to approximately 40 months ]
    All events of HF hospitalization as confirmed by a CEC.

  4. Time to First Occurrence of Composite Endpoint of All-Cause Mortality or HF Hospitalization [ Time Frame: From date of randomization until the date of first occurrence of death or HF hospitalization, assessed up to approximately 40 months ]
    The first event of death due to any cause or HF hospitalization as confirmed by a CEC.

  5. Time to All-Cause Mortality [ Time Frame: From date of randomization until the date of death, assessed up to approximately 40 months ]
    The first event of death due to any cause as confirmed by a CEC.

  6. Percentage of Participants who Experienced One or More Selected Nonserious Adverse Events (NSAEs) [ Time Frame: Up to approximately 40 months ]
    An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. Selected NSAEs are nonserious AEs that meet any of the following criteria: AEs that lead to study intervention dose modification or discontinuation, AEs that lead to withdrawal from the study, or coronavirus disease (COVID-19) disease-related AEs.

  7. Percentage of Participants Who Experienced One or More Serious Adverse Events (SAEs) [ Time Frame: Up to approximately 40 months ]
    An SAE is defined as any untoward medical occurrence that, at any dose: Results in death, is life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is another important medical event, as judged medically or scientifically, that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed above.

  8. Percentage of Participants Who Experienced One or More Events of Clinical Interest (ECIs) [ Time Frame: Up to approximately 40 months ]
    Events of clinical interest will include: 1) Potential drug-induced liver injury (DILI) events defined as: elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) laboratory value that is greater than or equal to 3X the upper limit of normal (ULN) and an elevated total bilirubin laboratory value that is greater than or equal to 2X the ULN and, at the same time, an alkaline phosphatase laboratory value that is less than 2X the ULN, as determined by way of protocol specified laboratory testing or unscheduled laboratory testing, 2) Symptomatic hypotension 3) Anemia.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of chronic HF [New York Heart Association (NYHA) Class II to IV] on guideline-directed medical therapy for heart failure (GDMT) with no HF hospitalization within 6 months or outpatient IV diuretic use within 3 months before randomization.
  • Left ventricular ejection fraction (LVEF) of ≤40%, assessed within 12 months before randomization by any imaging method.
  • Elevated N-terminal pro-brain natriuretic peptide (NT-proBNP) levels.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, is not a woman of childbearing potential (WOCBP), or is a WOCBP and agrees to follow contraceptive guidance during the study intervention period and for at least 1 month after the last dose of study intervention.

Exclusion Criteria:

  • Has SBP <100 mm Hg or symptomatic hypotension.
  • Awaiting heart transplantation, is receiving continuous IV infusion of an inotrope, or has or anticipates receiving an implanted ventricular assist device.
  • Amyloidosis or sarcoidosis.
  • Primary valvular heart disease requiring surgical procedure or intervention or has undergone a valvular surgical procedure or intervention within 3 months before randomization.
  • Hypertrophic cardiomyopathy.
  • Acute myocarditis or Takotsubo cardiomyopathy.
  • History of heart transplant.
  • Tachycardia-induced cardiomyopathy and/or uncontrolled tachyarrhythmia.
  • Acute coronary syndrome, or undergone coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) within 3 months before randomization.
  • History of symptomatic carotid stenosis, transient ischemic attack (TIA), or stroke within 3 months before randomization.
  • Malignancy or other noncardiac condition limiting life expectancy to <3 years.
  • Requires continuous home oxygen for severe pulmonary disease.
  • Interstitial lung disease.
  • Discontinuation or dose modification of GDMT or vericiguat within 4 weeks before randomization.
  • Recent history (within the last year) of drug or alcohol abuse or dependence.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05093933


Locations
Show Show 519 study locations
Sponsors and Collaborators
Merck Sharp & Dohme LLC
Investigators
Layout table for investigator information
Study Director: Medical Director Merck Sharp & Dohme LLC
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Publications of Results:

Layout table for additonal information
Responsible Party: Merck Sharp & Dohme LLC
ClinicalTrials.gov Identifier: NCT05093933    
Other Study ID Numbers: 1242-035
MK-1242-035 ( Other Identifier: Merck )
2022-500881-80-00 ( Registry Identifier: EU CT )
2020-005941-18 ( EudraCT Number )
First Posted: October 26, 2021    Key Record Dates
Last Update Posted: February 14, 2024
Last Verified: February 2024
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf
URL: http://engagezone.msd.com/ds_documentation.php

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases